Notice Number: NOT-TR-16-013
Key Dates
Release Date: April 28, 2016
NOT-TR-16-012, PAR-15-172, PAR-15-173
Issued by
National Center for Advancing Translational Sciences (NCATS)
Purpose
The purpose of this Notice is to modify PAR-15-172, in view of the early expiration of PAR-15-173, in order to remove references to the X02 pre-application process. Instead, applicants are encouraged to contact the NCATS Scientific/Research contact to discuss programmatic priority.
Funding Opportunity Purpose
Currently reads:
The purpose of this funding opportunity announcement (FOA) is to invite applications to stimulate innovative collaborative research in the NCATS’ Clinical and Translational Science Award (CTSA) consortium.
PAR-15-173 encourages X02 pre-applications for the CTSA Innovation Award Program. X02 applications will be evaluated by outside experts, and applicants whose X02 pre-applications are found to be meritorious and programmatically relevant will be notified of the opportunity to submit a full application in response to this U01 FOA.
Modified to read:
The purpose of this funding opportunity announcement (FOA) is to invite applications to stimulate innovative collaborative research in the NCATS’ Clinical and Translational Science Award (CTSA) consortium.
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Currently reads:
Purpose
Translating biomedical discoveries into clinical applications is essential to improving human health. It is also a complex process with high costs and substantial failure rates. These failures can result in delays of years or decades before improved patient outcomes result from discoveries in biomedical research. The Clinical and Translational Science Award (CTSA) hubs promote advances in translational research and training at participating medical research institutions. This funding opportunity announcement (FOA) will enable innovative collaborations among CTSA hubs to overcome system-wide barriers to translational effectiveness.
The scientific and operational issues which underlie most translational inefficiency are not specific to a particular disease, discipline, institution, or geographic locale. Rather, they are systematic issues, which require systematic and generalizable solutions. Further, every stage of the translational process, from target validation through intervention development to public health benefit assessment, is currently fraught with ineffectiveness and in need of bold, innovative new solutions. There is therefore a corresponding need for bold and innovative new experimental approaches to identifying such solutions. NCATS' catalysis of the development, demonstration, and dissemination of innovations across the spectrum of translational science will advance its mission to transform the effectiveness of translation of discoveries from the laboratory, clinic, and community into tangible benefits to human health.
This FOA is one of several sequential steps being taken by NCATS to evolve the CTSA program to augment its ability to, as suggested by a recent Institute of Medicine program report (http://www.iom.edu/Reports/2013/The-CTSA-Program-at-NIH-Opportunities-for-Advancing-Clinical-and-Translational-Research.aspx), “enhance the transit of therapeutics, diagnostics, and preventive interventions along the developmental pipeline; disseminate innovative translational research methods and best practices; and provide leadership in informatics standards and policy development to promote shared resources”.
Individual CTSA hubs, and more recently groups of hubs, have developed and demonstrated the utility of innovations that improve the efficiency and effectiveness of many aspects of translational research and training. The diversity of CTSA hubs, and their multiplicity nationwide, suggests that fostering cross-CTSA innovation development and implementation could transform the nation's translational effectiveness in unprecedented ways. This FOA therefore seeks to encourage all CTSA hubs to collaboratively conceptualize, develop, and implement multi-site innovative experimental approaches that overcome translational barriers in science, operations, and training.
We expect that, collectively, the projects funded under this FOA will have a transformative impact on the nation's translational science enterprise.
Modified to read:
Purpose
Translating biomedical discoveries into clinical applications is essential to improving human health. It is also a complex process with high costs and substantial failure rates. These failures can result in delays of years or decades before improved patient outcomes result from discoveries in biomedical research. The Clinical and Translational Science Award (CTSA) hubs promote advances in translational research and training at participating medical research institutions. This funding opportunity announcement (FOA) will enable innovative collaborations among CTSA hubs to overcome system-wide barriers to translational effectiveness.
The scientific and operational issues which underlie most translational inefficiency are not specific to a particular disease, discipline, institution, or geographic locale. Rather, they are systematic issues, which require systematic and generalizable solutions. Further, every stage of the translational process, from target validation through intervention development to public health benefit assessment, is currently fraught with ineffectiveness and in need of bold, innovative new solutions. There is therefore a corresponding need for bold and innovative new experimental approaches to identifying such solutions. NCATS' catalysis of the development, demonstration, and dissemination of innovations across the spectrum of translational science will advance its mission to transform the effectiveness of translation of discoveries from the laboratory, clinic, and community into tangible benefits to human health.
This FOA is one of several sequential steps being taken by NCATS to evolve the CTSA program to augment its ability to, as suggested by a recent Institute of Medicine program report (http://www.iom.edu/Reports/2013/The-CTSA-Program-at-NIH-Opportunities-for-Advancing-Clinical-and-Translational-Research.aspx), “enhance the transit of therapeutics, diagnostics, and preventive interventions along the developmental pipeline; disseminate innovative translational research methods and best practices; and provide leadership in informatics standards and policy development to promote shared resources”.
Individual CTSA hubs, and more recently groups of hubs, have developed and demonstrated the utility of innovations that improve the efficiency and effectiveness of many aspects of translational research and training. The diversity of CTSA hubs, and their multiplicity nationwide, suggests that fostering cross-CTSA innovation development and implementation could transform the nation's translational effectiveness in unprecedented ways. This FOA therefore seeks to encourage all CTSA hubs to collaboratively conceptualize, develop, and implement multi-site innovative experimental approaches that overcome translational barriers in science, operations, and training.
We expect that, collectively, the projects funded under this FOA will have a transformative impact on the nation's translational science enterprise.
Investigators are strongly encouraged to contact NCATS Scientific/Research contact to discuss the programmatic priority of their innovation prior to preparing an application.
No other changes are being made to this FOA
Inquiries
Please direct all inquiries to:
Philip J. Brooks, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-443-0513
Email: CTSAINNOVATIONFOAQuestions@mail.nih.gov
and Human Services (HHS)
